Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy

Pharmacology and Therapeutics

Volumn 152, Issue , 2015, Pages 18-27

  Spagnolo, P ^a,b   Maher, T M ^c,d   Richeldi, L ^e  

^a KANTONSSPITAL LIESTAL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c National Institute for Health Research Biological Research Unit Royal Brompton Hospital ^*  (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e University Hospital Southampton NHS Foundation Trust   (United Kingdom)

Author keywords

Clinical trials; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone; Therapy; Treatment

Indexed keywords

ACETYLCYSTEINE; ANTIFIBROTIC AGENT; AZATHIOPRINE; NINTEDANIB; PIRFENIDONE; PREDNISONE; WARFARIN; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CLINICAL PRACTICE; DRUG INDUSTRY; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LIPID PEROXIDATION; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW (TOPIC); ANIMAL; IDIOPATHIC PULMONARY FIBROSIS; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84933675401     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.04.005     Document Type: Review

References (69)

1. A. Azuma, T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, and K. Nakata Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 171 2005 1040 1047
2. J. Behr, K. Maier, B. Degenkolb, F. Krombach, and C. Vogelmeier Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression Am J Respir Crit Care Med 156 1997 1897 1901
3. J.A. Bjoraker, J.H. Ryu, M.K. Edwin, J.L. Myers, H.D. Tazelaar, and D.R. Schroeder Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 157 1998 199 203
4. A.M. Cantin, R.C. Hubbard, and R.G. Crystal Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis Am Rev Respir Dis 139 1989 370 372
5. N.I. Chaudhary, G.J. Roth, F. Hilberg, J. Müller-Quernheim, A. Prasse, and G. Zissel Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Eur Respir J 29 2007 976 985
6. H.R. Collard Idiopathic pulmonary fibrosis and pirfenidone Eur Respir J 35 2010 728 729
7. H.R. Collard, B.B. Moore, K.R. Flaherty, K.K. Brown, R.J. Kaner, and T.E. King Jr. Acute exacerbations of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 176 2007 636 643
8. C.E. Daniels, J.A. Lasky, A.H. Limper, K. Mieras, E. Gabor, and D.R. Schroeder Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am J Respir Crit Care Med 181 2010 604 610
9. M. Demedts, J. Behr, R. Buhl, U. Costabel, R. Dekhuijzen, and H.M. Jansen High-dose acetylcysteine in idiopathic pulmonary fibrosis N Engl J Med 353 2005 2229 2242
10. R.M. du Bois, C. Albera, W.Z. Bradford, U. Costabel, J.A. Leff, and P.W. Noble 6-minute walk test distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis Eur Respir J 43 2014 1421 1429
11. R.M. du Bois, S.D. Nathan, L. Richeldi, M.I. Schwarz, and P.W. Noble Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials Am J Respir Crit Care Med 186 2012 712 715
12. R.M. du Bois, D. Weycker, C. Albera, W.Z. Bradford, U. Costabel, and A. Kartashov Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference Am J Respir Crit Care Med 184 2011 1382 1389
13. R.M. du Bois, D. Weycker, C. Albera, W.Z. Bradford, U. Costabel, and A. Kartashov Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference Am J Respir Crit Care Med 183 2011 1231 1237
14. C.D. Fell Idiopathic pulmonary fibrosis: phenotypes and comorbidities Clin Chest Med 33 2012 51 57
15. K.R. Flaherty, G.B. Toews, W.D. Travis, T.V. Colby, E.A. Kazerooni, and B.H. Gross Clinical significance of histological classification of idiopathic interstitial pneumonia Eur Respir J 19 2002 275 283
16. F. Hilberg, G.J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, and U. Tontsch-Grunt BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 68 2008 4774 4782
17. K.E. Hostettler, J. Zhong, E. Papakonstantinou, G. Karakiulakis, M. Tamm, and P. Seidel Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Respir Res 15 2014 157 (Epub ahead of print)
18. G.A. Hurst, P.B. Shaw, and C.A. LeMaistre Laboratory and clinical evaluation of the mucolytic properties of acetylcysteine Am Rev Respir Dis 96 1967 962 970
19. Idiopathic Pulmonary Fibrosis Clinical Research Network, F.J. Martinez, J.A. de Andrade, K.J. Anstrom, T.E. King Jr., and G. Raghu Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis N Engl J Med 366 2012 1968 1977
20. Idiopathic Pulmonary Fibrosis Clinical Research Network, F.J. Martinez, J.A. de Andrade, K.J. Anstrom, T.E. King Jr., and G. Raghu Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis N Engl J Med 370 2014 2093 2101
21. Idiopathic Pulmonary Fibrosis Clinical Research Network, D.A. Zisman, M. Schwarz, K.J. Anstrom, H.R. Collard, and K.R. Flaherty A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis N Engl J Med 363 2010 620 628
22. S.N. Iyer, G. Gurujeyalakshmi, and S.N. Giri Effects of pirfenidone on transforming growth factor-b gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis J Pharmacol Exp Ther 291 1999 367 373
23. T. Kakugawa, H. Mukae, T. Hayashi, H. Ishii, K. Abe, and T. Fujii Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis Eur Respir J 24 2004 57 65
24. S. Kaul, and G.A. Diamond Trial and error: how to avoid commonly encountered limitations of published clinical trials J Am Coll Cardiol 55 2010 415 427
25. T.E. King, C. Albera, W.Z. Bradford, U. Costabel, R.M. du Bois, and J.A. Leff All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials Am J Respir Crit Care Med 189 2014 825 831
26. T.E. King Jr., C. Albera, W.Z. Bradford, U. Costabel, P. Hormel, and L. Lancaster Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial Lancet 374 2009 222 228
27. T.E. King Jr., J. Behr, K.K. Brown, R.M. du Bois, L. Lancaster, and J.A. de Andrade BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 177 2008 75 81
28. T.E. King Jr., W.Z. Bradford, S. Castro-Bernardini, E.A. Fagan, I. Glaspole, and M.K. Glassberg A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N Engl J Med 370 2014 2083 2092
29. T.E. King Jr., K.K. Brown, G. Raghu, R.M. du Bois, D.A. Lynch, and F. Martinez BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 184 2011 92 99
30. T.E. King Jr., A. Pardo, and M. Selman Idiopathic pulmonary fibrosis Lancet 378 2011 1949 1961
31. T.E. King Jr., M.I. Schwarz, K. Brown, J.A. Tooze, T.V. Colby, and J.A. Waldron Jr. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality Am J Respir Crit Care Med 164 2001 1025 1032
32. H. Kubo, K. Nakayama, M. Yanai, T. Suzuki, M. Yamaya, and M. Watanabe Anticoagulant therapy for idiopathic pulmonary fibrosis Chest 128 2005 1475 1482
33. J. Lasky Pirfenidone IDrugs Investig Drugs J 7 2004 166 172
34. B. Ley, H.R. Collard, and T.E. King Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 183 2011 431 440
35. T.M. Maher Pirfenidone in idiopathic pulmonary fibrosis Drugs Today (Barc) 46 2010 473 482
36. T.M. Maher Idiopathic pulmonary fibrosis: pathobiology and novel approaches to treatment Clin Chest Med 33 2012 69 83
37. T.M. Maher, and A.U. Wells Lost in translation; from animal models of pulmonary fibrosis to human disease Respirology 14 2009 915 916
38. T.M. Maher, A.U. Wells, and G.J. Laurent Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 30 2007 835 839
39. M.A. Malouf, P. Hopkins, G. Snell, A.R. Glanville, and Everolimus in IPF Study Investigators An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis Respirology 16 2011 776 783
40. F.J. Martinez, S. Safrin, D. Weycker, K.M. Starko, W.Z. Bradford, and T.E. King Jr. The clinical course of patients with idiopathic pulmonary fibrosis Ann Intern Med 142 2005 963 967
41. P.J. Millea N-acetylcysteine: multiple clinical applications Am Fam Physician 80 2009 265 269
42. A. Moeller, K. Ask, D. Warburton, J. Gauldie, and M. Kolb The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40 2008 362 382
43. S.D. Nathan, O.A. Shlobin, N. Weir, S. Ahmad, J.M. Kaldjob, and E. Battle Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium Chest 140 2011 221 229
44. V. Navaratnam, K.M. Fleming, J. West, C.J. Smith, R.G. Jenkins, and A. Fogarty The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 66 2011 462 467
45. A.G. Nicholson, T.V. Colby, R.M. du Bois, D.M. Hansell, and A.U. Wells The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis Am J Respir Crit Care Med 162 2000 2213 2217
46. P.W. Noble, C. Albera, W.Z. Bradford, U. Costabel, M.K. Glassberg, and D. Kardatzke Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 377 2011 1760 1769
47. I. Noth, K.J. Anstrom, S.B. Calvert, J. de Andrade, K.R. Flaherty, and C. Glazer A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 186 2012 88 95
48. H. Oku, T. Shimizu, T. Kawabata, M. Nagira, I. Hikita, and A. Ueyama Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis Eur J Pharmacol 590 2008 400 408
49. G. Raghu, J. Behr, K.K. Brown, J.J. Egan, S.M. Kawut, and K.R. Flaherty Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial Ann Intern Med 158 2013 641 649
50. G. Raghu, K.K. Brown, W.Z. Bradford, K. Starko, P.W. Noble, and D.A. Schwartz A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis N Engl J Med 350 2004 125 133
51. G. Raghu, K.K. Brown, U. Costabel, V. Cottin, R.M. du Bois, and J.A. Lasky Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial Am J Respir Crit Care Med 178 2008 948 955
52. G. Raghu, S.-Y. Chen, W.-S. Yeh, B. Maroni, Q. Li, and Y.C. Lee Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence and survival, 2001-11 Lancet Respir Med 2 2014 566 572
53. G. Raghu, H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, and K.K. Brown An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 2011 788 824
54. G. Raghu, W.C. Johnson, D. Lockhart, and Y. Mageto Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study Am J Respir Crit Care Med 159 1999 1061 1069
55. G. Raghu, R. Million-Rousseau, A. Morganti, L. Perchenet, J. Behr, and MUSIC Study Group Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Eur Respir J 42 2013 1622 1632
56. L. Richeldi, U. Costabel, and M. Selman Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N Engl J Med 365 2011 1079 1087
57. L. Richeldi, R.M. du Bois, G. Raghu, A. Azuma, K.K. Brown, and U. Costabel Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 370 2014 2071 2082
58. C.J. Schaefer, D.W. Rurhmund, L. Pan, S.D. Seiwert, and K. Kossen Antifibrotic activities of pirfenidone in animal models Eur Respir Rev 20 2011 85 97
59. G. Schoenheit, I. Becattelli, and A.H. Cohen Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients Chron Respir Dis 8 2011 225 231
60. H.J. Schunemann, R. Jaeschke, D.J. Cook, W.F. Bria, A.A. El-Solh, and A. Ernst An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations Am J Respir Crit Care Med 174 2006 605 614
61. M. Selman, and A. Pardo Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model Am J Respir Crit Care Med 189 2014 1161 1172
62. L. Shulgina, A.P. Cahn, E.R. Chilvers, H. Parfrey, A.B. Clark, and E.C. Wilson Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial Thorax 68 2013 155 162
63. P. Spagnolo, V. Cottin, and R.M. du Bois Rare lung disease and orphan drug development Lancet Respir Med 1 2013 479 487
64. P. Spagnolo, C. Del Giovane, F. Luppi, S. Cerri, S. Balduzzi, and E.H. Walters Non-steroid agents for idiopathic pulmonary fibrosis Cochrane Database Syst Rev 9 2010 (CD003134)
65. P. Spagnolo, J. Grunewald, and R.M. du Bois Genetic determinants of pulmonary fibrosis: evolving concepts Lancet Respir Med 2 2014 416 428
66. H. Taniguchi, M. Ebina, Y. Kondoh, T. Ogura, A. Azuma, and M. Suga Pirfenidone in idiopathic pulmonary fibrosis Eur Respir J 35 2010 821 829
67. W.D. Travis, U. Costabel, D.M. Hansell, T.E. King Jr., D.A. Lynch, and A.G. Nicholson An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias Am J Respir Crit Care Med 188 2013 733 748
68. D. Valeyre, C. Albera, W.Z. Bradford, U. Costabel, T.E. King Jr., and J.A. Leff Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis Respirology 19 2014 740 747
69. L. Wollin, I. Maillet, V. Quesniaux, A. Holweg, and B. Ryffel Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis J Pharmacol Exp Ther 349 2014 209 220